Gynaecological Infections
Nexbiome Therapeutics focuses on gynaecological conditions involving acute vaginal infection, with research activity centered on women diagnosed with bacterial vaginosis, vulvovaginal candidiasis, and mixed infectious presentations.
- Bacterial vaginosis
- Vulvovaginal candidiasis
- Mixed vaginal infection
The sponsor’s current clinical activity is directed toward treatment options for symptomatic vaginal dysbiosis and infection in women.
Microbiome-Based Therapeutics
The company is involved in research on a live biotherapeutic product designed for vaginal administration, reflecting an interest in microbiome-oriented approaches for managing infectious and inflammatory conditions of the female reproductive tract.
- Live biotherapeutic product
- Vaginal tablet
- Microbiome-targeted treatment
This area links therapeutic development with restoration of the local vaginal microbiota in acute infection.
Infectious Disease Treatment
Research activity extends to the treatment of acute infectious disease in the vaginal setting, with attention to therapeutic efficacy, safety, and symptom resolution in short-term clinical management.
- Acute vaginal infection
- Antiinfective therapy
- Symptom control
The sponsor’s interest is concentrated on first-line management of infection-related conditions affecting women’s health.
Women’s Health
Nexbiome Therapeutics’ clinical research reflects a focus on women’s health, particularly disorders of the vaginal environment and reproductive tract infections that require targeted therapeutic options.
- Female reproductive tract
- Vaginal health
- Recurrent infection management
Its current trial activity is centered on treatment strategies for women with confirmed gynaecological infection.
